Results 71 to 80 of about 248,205 (145)

Epigenetic evolution and lineage histories of chronic lymphocytic leukemia

Nature, 2019
Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary course of cancer1. Chronic lymphocytic leukaemia (CLL) is a highly informative model for cancer evolution as it undergoes substantial genetic diversification and ...
Federico Gaiti, R. Chaligné, H. Gu, Ryan Brand, S. Kothen-Hill, Rafael C. Schulman, K. Grigorev, D. Risso, Kyu-Tae Kim, A. Pastore, Kevin Y. Huang, A. Alonso, Caroline Sheridan, Nathaniel D. Omans, Evan Biederstedt, Kendell Clement, Lili Wang, Joshua A. Felsenfeld, E. Bhavsar, Martin J. Aryee, J. Allan, R. Furman, A. Gnirke, Catherine J. Wu, A. Meissner, D. Landau   +25 more
semanticscholar   +1 more source

Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. [PDF]

, 2004
We studied the actions of geldanamycin (GA) and herbimycin A (HMA), inhibitors of the chaperone proteins Hsp90 and GRP94, on B chronic lymphocytic leukemia (CLL) cells in vitro.
Addison, E, Folarin, NI, Ganeshaguru, K, Hoffbrand, AV, Jones, DT, Lowdell, MW, Mehta, AB, North, JM, Wickremasinghe, RG   +8 more
core   +1 more source

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Blood, 2019
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic ...
P. Baliakas, S. Jeromin, M. Iskas, A. Puiggros, K. Plevová, K. Plevová, F. Nguyen‐Khac, Z. Davis, G. Rigolin, A. Visentin, A. Xochelli, J. Delgado, F. Baran-Marszak, E. Stalika, P. Abrisqueta, Kristina Ďurechová, G. Papaioannou, V. Eclache, M. Dimou, T. Iliakis, R. Collado, M. Doubek, M. Doubek, M. Calasanz, Neus Ruiz‐Xivillé, C. Moreno, M. Jarošová, M. Jarošová, A. Leeksma, P. Panayiotidis, H. Podgornik, F. Cymbalista, A. Anagnostopoulos, L. Trentin, N. Stavroyianni, F. Davi, P. Ghia, A. Kater, A. Cuneo, Š. Pospíšilová, Š. Pospíšilová, B. Espinet, A. Athanasiadou, D. Oscier, C. Haferlach, K. Stamatopoulos   +45 more
semanticscholar   +1 more source

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. [PDF]

, 2019
Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment
Hasan, Md Kamrul, Kipps, Thomas J, Rassenti, Laura, Widhopf, George F, Yu, Jian   +4 more
core   +1 more source

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Blood Advances, 2019
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation.
F. Awan, A. Schuh, Jennifer R. Brown, R. Furman, J. Pagel, P. Hillmen, D. Stephens, J. Woyach, E. Bibikova, P. Charuworn, M. Frigault, A. Hamdy, R. Izumi, B. Linghu, P. Patel, M. Wang, J. Byrd   +16 more
semanticscholar   +1 more source

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT [PDF]

, 2018
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation ...
Beelen, Dietrich, Bittenbring, Jörg, Blaise, Didier, Blok, Henric-Jan, Castagna, Luca, Chevallier, Patrice, Ciceri, Fabio, Corradini, Paolo, Eikema, Dirk-Jan, Foá, Roberto, Hallek, Michael, Hilgendorf, Inken, Koc, Yener, Kröger, Nicolaus, Moreno, Carol, Müller, Lutz Peter, Schetelig, Johannes, Selleslag, Dominik, Solano, Carlos, Theobald, Matthias, Tischer, Johanna, van Gelder, Michel, van Gorkom, Gwendolyn, van Lint, M. T.   +23 more
core   +1 more source

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

Haematologica, 2019
Venetoclax is a first in class, highly specific antagonist of BCL2 and supersedes current standard treatments in haematologic malignancies as recently demonstrated in the MURANO trial.
E. Tausch, William L. Close, A. Dolnik, J. Bloehdorn, B. Chyla, L. Bullinger, H. Döhner, D. Mertens, S. Stilgenbauer   +8 more
semanticscholar   +1 more source

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. [PDF]

, 2018
Not ...
Bomben, R, Bonina, S, Cafforio, L, Cappelli, Lv, Cuneo, A, Dal Bo, M, Del Giudice, I, Del Poeta, G, Diop, F, Favini, C, Foá, R., Gaidano, G, Gattei, V, Guarini, A, Ilari, C, Mariglia, P, Marinelli, M, Mauro, Fr, Messina, M, Peragine, N, Piciocchi, A, Raponi, S, Rigolin, Gm, Rossi, D, Rossi, F   +24 more
core   +1 more source

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Blood, 2019
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled
A. Roberts, Shuo Ma, T. Kipps, S. Coutre, M. Davids, B. Eichhorst, M. Hallek, J. Byrd, K. Humphrey, Lang Zhou, B. Chyla, J. Nielsen, J. Potluri, S. Y. Kim, M. Verdugo, S. Stilgenbauer, W. Wierda, J. Seymour   +17 more
semanticscholar   +1 more source

Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment [PDF]

, 2004
Diagnosis and treatment of chronic lymphatic leukaemia (CLL) are currently undergoing great change. New knowledge of prognosis factors and the numerous new therapeutic procedures now available, such as purine analogues, high-dose treatment and monoclonal
Bergmann, M., Emmerich, B., Hallek, M.
core   +1 more source